Impact of Early Debriefing and Enhanced Educative Components on Direct Oral Anticoagulant Adherence After Venous Thromboembolism. (DEBRIEF-VTE)

December 1, 2020 updated by: University Hospital, Brest

Impact of Early Debriefing and Enhanced Educative Components on Direct Oral Anticoagulant Adherence After Venous Thromboembolism. The DEBRIEF-VTE Study

Venous thromboembolism (VTE) is a frequent multifactorial and potential life-threatening disease. Once VTE has been diagnosed, anticoagulation should be started and prolonged for at least three to six months in order to reduce the risk of fatal and non-fatal recurrences and long-term sequelae. The development of direct oral anticoagulants (DOACs) has represented a major advance in patients' care as there is evidence that DOACs are associated with a decreased risk of bleeding without loss in efficacy and as it simplifies treatment modalities for the patients and the physician. However, as DOACs do not require laboratory monitoring, adherence of anticoagulation is difficult to evaluate and traditional programs built on patients receiving VKA may no longer be applicable to patients on DOAC. In order to increase treatment adherence in patients on DOAC for an acute VTE and to improve the quality of life, the impact of specific educational programs on DOACs, taking in account both therapeutic (DOAC) and medical illness (VTE) dimensions needs to be investigated.

In patients with an acute episode of VTE treated for at least 6 months, the main hypothesis is that early debriefing and educative components added to a standardized visit one month after an acute VTE has the potential to improve patient's adherence to APIXABAN therapy at 6 months of follow-up.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

Venous thromboembolism (VTE) is a frequent multifactorial and potential life-threatening disease. Once VTE has been diagnosed, anticoagulation should be started and prolonged for at least three to six months in order to reduce the risk of fatal and non-fatal recurrences and long-term sequelae. The development of direct oral anticoagulants (DOACs) has represented a major advance in patients' care as there is evidence that DOACs are associated with a decreased risk of bleeding without loss in efficacy and as it simplifies treatment modalities for the patients and the physician. However, as DOACs do not require laboratory monitoring, adherence of anticoagulation is difficult to evaluate and traditional programs built on patients receiving VKA may no longer be applicable to patients on DOAC. In order to increase treatment adherence in patients on DOAC for an acute VTE and to improve the quality of life, the impact of specific educational programs on DOACs, taking in account both therapeutic (DOAC) and medical illness (VTE) dimensions needs to be investigated.

Design The "DEBRIEF-VTE" trial is a multicenter randomized trial with blind evaluation and using a Zelen randomization process comparing a standardized follow-up visit at one month associated with a "debriefing and enhanced educative components" versus a standardized follow-up visit at one month alone (i.e.; without debriefing process).

All patients meeting the inclusion and none of the exclusion criteria are eligible for randomization. They will be randomized 1:1 to one of two allocated groups:

  • Experimental group: a standardized follow-up visit at one month associated with "debriefing and enhanced educative component"
  • Control group: a standardized follow-up visit at one month alone (i.e.; without "debriefing and educative component") Randomization will be performed using a two-step methodology described by Zelen et al.

  • Stratification by:

    • Center
    • DVT or PE
    • Presence of a major risk factor (either transient or persistent) or not (unprovoked VTE) At visit 1 (inclusion, 0-7 days): Inclusion of patients using the first written informed consent to accept a standard follow-up (visit at 1 month and 6 months) without mentioning randomization at one month performed in order to allocate patients to have, or to not have, debriefing and enhanced educative components. Study medication will be administered with complete explanation about doses and a classical therapeutic information regarding DOAC and clinical signs of recurrent VTE and bleeding (one treatment box with 400 pills of apixaban at 5 mg for the first 6 months of therapy) will be performed.

Visit 2 (30 days):

  • Before the visit 2, review of all the inclusion and exclusion criteria and compute creatinine clearance using Cockcroft-Gault method ; if all eligibility criteria are satisfied, randomization of the patient;

  • After randomization, during the visit 2:

    • For patients allocated to the experimental group: signature of the second written informed consent describing the debriefing and enhanced educative components and objective on quality of life
    • For patients allocated to the control group: no second written informed consent is required

Visit 3/ET (180 days):

- Evaluate quality of life (PembQOL if PE, VEINES-Qol if DVT, EQ-5D for all patients), residual symptoms (mMRC and MDP scale if PE, Villalta if DVT) depression (HAD), recurrent VTE, bleeding, hospitalizations, death

The primary objective is to demonstrate that, in patients with an acute episode of VTE treated for at least 6 months, early debriefing and enhanced educative components added to a standardized visit one month after an acute VTE is associated with an increased adherence to apixaban therapy at 6 months than after a standardized visit alone at one month (adherence measured by the MEMSCap™ Medication Event Monitoring System Cap (WestRock, USA & Switzerland). In patients with an acute episode of VTE treated for at least 6 months, the main hypothesis is that early debriefing and educative components added to a standardized visit one month after an acute VTE has the potential to improve patient's adherence to APIXABAN therapy at 6 months of follow-up.

Secondary objectives are to evaluate the impact of early debriefing and enhanced educative components added to a standardized visit one month after an acute VTE on the following at 6 months of treatment : quality of life (EQ-5D for all, PembQOL if PE, VEINES-Qol if DVT), residual symptoms (MMRC and multidimensional dyspnea profile(MDP) scales if PE, Villalta if DVT), depression (HAD), recurrent VTE, bleeding,hospitalizations and death.

150 patients will be included Duration of the inclusion period: 18 months Duration of participation for each patient: 6 months Total duration of the study: 24 months

Study Type

Interventional

Enrollment (Anticipated)

150

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients >18 years old, the upper limit of which will be left to the discretion of the investigator according to the risk benefit balance
  • Patients with indications for a minimum of 6 months of anticoagulation after an acute documented VTE that was diagnosed 7 days ago or less (i.e.; symptomatic PE or proximal or distal DVT)
  • Social security affiliation.
  • Patient who signed inform consent form

Exclusion Criteria:

  • Known allergy to apixaban, allergy to any of the excipients
  • Unable or refusal to give informed consent
  • Indication for anticoagulation other than DVT or PE (e.g.; atrial fibrillation, mechanic valves…)
  • Treatment with investigational drug in the past 1 month
  • Chronic liver disease or chronic hepatitis
  • Renal insufficiency with creatinine <30 ml / min on Cockcroft and Gault formula
  • Known antiphospholipid syndrome
  • Dual anti-platelet therapy or aspirin at dosage >100 mg per day
  • Concomitant use of a strong inhibitor of cytochrome P450 3A4 (CYP3A4) (e.g., a protease inhibitor for human immunodeficiency virus infection or azole-antimycotics agents ketoconazole, itraconazole, voriconazole, posaconazole) or a CYP3A4 inducer (e.g., rifampin, carbamazepine, or phenytoin),
  • Active cancer of less than 6 months
  • Active pregnancy or expected pregnancy in the next 6 months
  • Planned surgery in the next 6 months
  • No effective contraception in women of childbearing age
  • Life expectancy <6 months
  • Patient with active clinically significant bleeding
  • Patient with lesion or condition if considered a significant risk factor for major bleeding
  • Patient with concomitant treatment with any other anticoagulant agent
  • Patient with concomitant treatment as: P-gp inhibitors: ciclosporin, dronedarone, quinidine, verapamil, protease inhibitors (e.g.: ritonavir, nelfinavir, indinavir, saquinavir), macrolides (e.g.; erythromycin, clarithromycine), azole antifungals (e.g.; ketoconazole, itraconazole, voriconazole, posaconazole).
  • Patient with concomitant treatment as non steroidal antiinflammatory drugs
  • Patient with low body weight (< 60kg).
  • Patients with breast-feeding

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Debriefing
a standardized follow-up visit at one month associated with "debriefing and enhanced educative component"
Other: Debriefing and educative components
The patient will receive early debriefing and enhanced educative components added to a standardized visit at one month
Other: Without debriefing
a standardized follow-up visit at one month alone (i.e.; without "debriefing and educative component")
Other: Without debriefing and educative components
Patient will receive a standardized visit alone (without debriefing and enhanced educative components ) at one month

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Treatment adherence mesured by Medication Event Monitoring System Cap
Time Frame: at 6 months

Adherence to apixaban therapy at 6 months after an acute episode of VTE measured by the MEMSCap™ will be evaluated.

The main criteria for adherence measurement will be the number of days where patients took adequately apixaban divided by the number of expected days of prescription. An additional evaluation will be the number of taken pills divided by the expected taken pills.
at 6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Treatment adherence mesured by Medication Event Monitoring System Cap
Time Frame: at 1 month and 3 months

Adherence to apixaban therapy at 1 month and 3 months after an acute episode of VTE measured by the MEMSCap™ will be evaluated.

The main criteria for adherence measurement will be the number of days where patients took adequately apixaban divided by the number of expected days of prescription. An additional evaluation will be the number of taken pills divided by the expected taken pills.
at 1 month and 3 months
Quality of life after an acute VTE
Time Frame: At 6 months
Quality of life of patients with VTE will be evaluated by the EQ-5D questionnaire
At 6 months
Quality of life after an acute VTE
Time Frame: At 6 months
Quality of life of patients with VTE will be evaluated by the HAD scale
At 6 months
Recurrent VTE (Symptomatic recurrent pulmonary embolism and Symptomatic recurrent deep-vein thrombosis) diagnosed on the basis of a clinical suspicion
Time Frame: during a study treatment period of 6 months
Adjudicated symptomatic objectively confirmed recurrent VTE (non fatal or fatal VTE) during the study treatment period
during a study treatment period of 6 months
Major and clinically relevant non major bleeding
Time Frame: during a study treatment period of 6 months
Adjudicated major bleeding (as defined by the criteria of the International Society of Thrombosis and Haemostasis) or clinically relevant non major bleeding during the study treatment period
during a study treatment period of 6 months
Mortality
Time Frame: during a study treatment period of 6 months
Mortality due to VTE, bleeding or other cause than recurrent VTE or major or clinically relevant non major bleeding during the study treatment period will be adjudicated
during a study treatment period of 6 months
Hospitalisation for an acute medical illness during treatment period will be evaluated by questioning the patient
Time Frame: during a study treatment period of 6 months
Hospitalization for an acute medical illness during treatement period will be evaluated by questioning the patient
during a study treatment period of 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Brest

Collaborators

Bristol-Myers Squibb

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 27, 2019

Primary Completion (Anticipated)

December 1, 2021

Study Completion (Anticipated)

December 1, 2021

Study Registration Dates

First Submitted

October 23, 2019

First Submitted That Met QC Criteria

October 24, 2019

First Posted (Actual)

October 28, 2019

Study Record Updates

Last Update Posted (Actual)

December 2, 2020

Last Update Submitted That Met QC Criteria

December 1, 2020

Last Verified

December 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 29BRC18.0198

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Venous Thromboembolism

Clinical Trials on Debriefing and educative components

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe